Consent given pursuant to sections 14 and 14A to the importation and supply of the therapeutic goods specified by Mallinckrodt Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. The 1989 Act was introduced to address the need for a comprehensive regulatory framework that governs the importation, manufacture, supply, and advertising of therapeutic goods. Enacted by the Commonwealth Parliament, the Act seeks to protect public health by establishing a system that manages risks associated with therapeutic goods. The legislative consent granted under sections 14 and 14A of the Act, on the application of Mallinckrodt Australia Pty Ltd, allows for the importation and supply of Technetium (99mTc) (TECHNESCAN MAG3) mertiatide powder for injection multidose vial, which does not conform to certain labelling requirements, thus addressing specific commercial needs while maintaining oversight to protect public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods in Australia, which include medicines, medical devices, blood and blood components, human tissue products, and complementary medicines. The Act applies to all persons and entities involved in the importation, supply, and manufacturing of these goods. It also regulates the conduct and transactions related to these goods, ensuring that they are of acceptable quality, safety, and efficacy. The Act has a national jurisdictional reach, as it is a Commonwealth Act, and applies to the whole of Australia. However, the Act may be subject to state and territory regulations that complement the national provisions. The Therapeutic Goods Order No. 69, which sets out the general requirements for labels for medicines, applies to all medicines supplied in Australia. In this case, the Act has been used to grant a consent to Mallinckrodt Australia Pty Ltd to import and supply Technetium (99mTc) (TECHNESCAN MAG3) mertiatide powder for injection multidose vial, which does not conform to the labelling requirements. The consent is subject to certain conditions, including that the current approved labels are used and that any queries or complaints are referred to the incoming sponsor, Landauer. The consent is effective for 12 months from the date of sponsorship transfer. The Act may be extended or restricted through subordinate instruments, such as regulations or codes of conduct, which provide further detail on specific aspects of the Act.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, play a critical role in regulating the importation and supply of therapeutic goods in Australia. Under these sections, the Secretary of the Department of Health, or a delegate, can grant consent for certain therapeutic goods to be imported and supplied, even if they do not strictly comply with the labelling requirements of the Therapeutic Goods Order No. 69 (paragraph 3(2)(l)). This consent can be sought by an entity such as Mallinckrodt Australia Pty Ltd, as was the case on 2 September 2015, when consent was granted for the importation and supply of a specific kit for the preparation of Technetium (99mTc) (TECHNESCAN MAG3) mertiatide powder for injection multidose vial. This particular consent was issued for a duration of 12 months, from 14 September 2015 to 13 September 2016, and is subject to certain conditions to ensure public safety and proper oversight. Entities granted consent under sections 14 and 14A of the Therapeutic Goods Act 1989 must adhere to specific obligations to maintain the integrity of the consent. In this case, the consent granted to Mallinckrodt Australia Pty Ltd is contingent on the continued use of the currently approved labels, which were provided with the application letter. Additionally, there must be arrangements in place for the referral of any queries or complaints concerning the products to the incoming sponsor, Landauer. This ensures that any issues related to the product are properly addressed and managed. Furthermore, the consent explicitly states that no other changes have been made to the product or its supply process, underscoring the importance of maintaining the status quo while these products are on the market. Failure to comply with the conditions of the consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989 can lead to serious legal consequences. While the specific offences and penalties are not detailed in the provided text, the Act generally imposes both civil and criminal penalties for breaches of therapeutic goods regulations. These can include fines, imprisonment, or both, depending on the severity of the breach and the intent behind it. The Therapeutic Goods Act 1989 and its associated regulations are designed to protect public health and safety, and any non-compliance can result in significant legal repercussions for the offending party.